ArticleChinese herbal medicines2026
Exploring possible mechanisms of antiviral effect of Shufeng Jiedu Capsule on viral pneumonia: A comprehensive analysis.
Article in Chinese herbal medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Influenza A virus (IAV) is a major cause of respiratory tract infections. Shufeng Jiedu Capsule (SFJD) has a broad-spectrum antiviral effect, however, it is not clear whether SFJD acts by targeting the immune-inflammatory pathway. The aim of this study was to elucidate the therapeutic effect and the mechanism of antiviral action of SFJD in mice with influenza virus pneumonia. Methods: In this study, a mouse model of influenza virus pneumonia was used to evaluate the efficacy of SFJD in the treatment of influenza virus pneumonia. Next, the potential pathways of action by which SFJD exerts its antiviral effects were analysed in conjunction with network pharmacology and and untargeted metabolomics. Finally, Results: SFJD significantly reduced lung index, lowered viral load, attenuated lung tissue lesions, modulated inflammatory metabolism in lung tissue, reduced macrophage inflammatory infiltration and protected lung epithelial cells in mice. The results of the network pharmacological analysis and metabolomics analysis suggested that SFJD might act through the Toll-like receptor 4(TLR4)/myeloid differentiation primary response protein 88(MyD88)/ TNF receptor associated factor (TRAF6)/nuclear factor kappa-B(NF- Conclusion: SFJD could effectively attenuate lung injury induced by influenza virus infection and provide a scientific basis for the protection of respiratory mucosal epithelial cells. SFJD could effectively alleviate lung injury by regulating the TLR4/MyD88/TRAF6/NF-κB signaling pathway, inhibiting the levels of TNF-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.